TABLE 4.
Differentially expressed genes (DEGs) involved in drug metabolism.
| Gene ID | Log2 ratio (T/C) | Regulation (T/C) | P-value | Protein | Metabolism detoxification process |
| LOC656161 | 4.28 | Up | 2.26E-65 | OBPC11 | Phase 0 |
| LOC660270 | 4.03 | Up | 0 | CYP4BN6 | Phase I |
| LOC100240681 | 2.12 | Up | 6.93E-09 | OBPC17 | Phase 0 |
| LOC664471 | 2.04 | Up | 5.36E-52 | CYP6BQ7 | Phase I |
| LOC658048 | 2.03 | Up | 2.33E-37 | CYP6A2 | Phase I |
| LOC107398166 | 1.91 | Up | 1.98E-07 | Ugt86Dg | Phase II |
| LOC664595 | 1.91 | Up | 2.23E-217 | OBP10 | Phase 0 |
| LOC662506 | 1.87 | Up | 0 | α-EST5 | Phase I |
| LOC657602 | 1.76 | Up | 3.47E-76 | GSTs6 | Phase II |
| LOC103313315 | 1.63 | Up | 6.44E-23 | CYP351A2 | Phase I |
| LOC100141953 | 1.58 | Up | 2.82E-06 | Ugt2B7-like | Phase II |
| LOC656937 | 1.47 | Up | 1.65E-114 | MRP4 | Phase III |
| LOC661102 | 1.43 | Up | 1.12E-09 | α-EST2 | Phase I |
| LOC664599 | 1.41 | Up | 5.71E-155 | OBPC02 | Phase 0 |
| LOC656243 | 1.40 | Up | 0 | OBPC12 | Phase 0 |
| LOC661621 | 1.37 | Up | 0 | α-EST6 | Phase I |
| LOC661270 | 1.36 | Up | 2.72E-31 | CSP12 | Phase 0 |
| LOC657697 | 1.33 | Up | 0 | CSP20 | Phase 0 |
| LOC664285 | 1.31 | Up | 2.63E-37 | CYP9Z2 | Phase I |
| LOC657454 | 1.27 | Up | 2.98E-30 | CYP9AC1 | Phase I |
| LOC661469 | 1.24 | Up | 0.000982 | CSP17 | Phase 0 |
| LOC656120 | 1.22 | Up | 1.19E-27 | Ugt2B16 | Phase II |
| LOC659847 | 1.15 | Up | 4.96E-63 | MRP49 | Phase III |
| LOC659009 | 1.13 | Up | 4.50E-45 | GSTs7 | Phase II |
| LOC656770 | 1.12 | Up | 6.93E-55 | CYP6BK11 | Phase I |
| LOC661219 | 1.12 | Up | 1.22E-37 | CSP11 | Phase 0 |
| LOC657560 | 1.07 | Up | 3.78E-13 | CYP6A14 | Phase I |
| LOC657825 | −1.12 | Down | 1.27E-15 | BG | Phase II |
| LOC100142486 | −1.17 | Down | 1.98E-46 | Ugt86Dc | Phase II |
| LOC656306 | −1.22 | Down | 3.25E-57 | CYP4BN5 | Phase I |
| LOC655331 | −1.24 | Down | 5.47E-242 | GSTe7 | Phase II |
| LOC655415 | −1.33 | Down | 3.03E-92 | GSTe8 | Phase II |
| LOC658886 | −1.42 | Down | 1.80E-08 | XDH | Phase I |
| LOC661967 | −1.48 | Down | 7.35E-79 | Ugt2B20 | Phase II |
| LOC659878 | −1.51 | Down | 1.31E-71 | CYP4Q1 | Phase I |
| LOC662300 | −1.99 | Down | 3.03E-22 | CYP351A3 | Phase I |
| LOC661799 | −2.15 | Down | 9.46E-10 | CSP8 | Phase 0 |
| LOC103313826 | −2.22 | Down | 8.77E-05 | FMO 2 | Phase I |
| LOC664598 | −2.25 | Down | 0 | OBPC01 | Phase 0 |
| LOC660846 | −2.44 | Down | 7.10E-103 | Ugt2C1 | Phase II |
| LOC662337 | −2.49 | Down | 6.97E-127 | CYP4C1 | Phase I |
| LOC107398495 | −2.77 | Down | 7.86E-25 | GSTe4 like | Phase II |
| LOC664475 | −2.87 | Down | 5.91E-05 | CYP6A20 | Phase I |
| LOC661930 | −3.09 | Down | 5.08E-05 | CYP349A1 | Phase I |
C, control; T, 5% A. vulgaris treatment; OBP, odorant binding protein; CYP, cytochrome P450; Ugt, UDP-glucuronosyltransferase; EST, esterase; GST, glutathione S-transferase; MRP, multidrug resistance protein; BG, beta-glucuronidase; XDH, xanthine dehydrogenase; FMO, flavin-containing monooxygenase.